RenovoRx, Inc.
$1
▲
1.03%
2026-04-21 09:12:00
renovorx.com
NCM: RNXT
Explore RenovoRx, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$45.05 M
Current Price
$1
52W High / Low
$1.45 / $0.7
Stock P/E
—
Book Value
$0.15
Dividend Yield
—
ROCE
-176.68%
ROE
-2.26%
Face Value
—
EPS
$-0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
1.22
Debt / Equity
3.91
Current Ratio
4.02
Quick Ratio
3.93
Forward P/E
-8.21
Price / Sales
41.49
Enterprise Value
$37.58 M
EV / EBITDA
-3.13
EV / Revenue
33.46
Rating
Strong Buy
Target Price
$6.88
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 2. | LENZ Therapeutics, Inc. | $10.13 | — | $319.19 M | — | -32.01% | -33.63% | $50.4 / $8.25 | $9.07 |
| 3. | ADMA Biologics, Inc. | $10.88 | 17.68 | $2.6 B | — | 34.51% | 35.56% | $25.67 / $7.21 | $2.01 |
| 4. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | Genprex, Inc. | $1.16 | — | $10.45 M | — | -194.32% | -3.39% | $55 / $1.15 | $3.78 |
| 7. | GridAI Technologies Corp. | $2.79 | — | $9.38 M | — | -27% | -58.82% | $5.84 / $0.97 | — |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.24 M | 0.27 M | 0.42 M | 0.2 M | 0.04 M | — |
| Operating Profit | -3.52 M | -3.2 M | -2.68 M | -3.11 M | -2.63 M | — |
| Net Profit | -2.94 M | -2.91 M | -2.9 M | -2.42 M | -2.88 M | — |
| EPS in Rs | -0.07 | -0.06 | -0.06 | -0.05 | -0.06 | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.12 M | 0.04 M | 0 M | 0 M |
| Operating Profit | -12.51 M | -10.97 M | -11.4 M | -9.95 M |
| Net Profit | -11.17 M | -8.81 M | -10.23 M | -9.89 M |
| EPS in Rs | -0.25 | -0.2 | -0.23 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.1 M | 8.12 M | 1.47 M | 7.26 M |
| Total Liabilities | 2.67 M | 3.64 M | 4.47 M | 1.1 M |
| Equity | 5.42 M | 4.48 M | -3 M | 6.16 M |
| Current Assets | 7.89 M | 7.83 M | 1.47 M | 7.26 M |
| Current Liabilities | 1.96 M | 1.91 M | 1.18 M | 1.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.97 M | -9.12 M | -10.26 M | -8.81 M |
| Investing CF | -0 M | -0.01 M | 2.03 M | -2.03 M |
| Financing CF | 10.85 M | 15.12 M | 5.01 M | 0.04 M |
| Free CF | -10.97 M | -9.14 M | -10.26 M | -8.81 M |
| Capex | -0 M | -0.01 M | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 13.86% | -3.47% | — | — |
| Profit Margin % | -20497.67% | — | — | — |
| Operating Margin % | -25511.63% | — | — | — |
| Gross Margin % | 100% | — | — | — |
| EBITDA Margin % | -25511.63% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.